Cargando…

Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma

Mostrar otras versiones (1)

The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but it remains unclear as to which peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusano, Y, Yokoyama, M, Terui, Y, Nishimura, N, Mishima, Y, Ueda, K, Tsuyama, N, Hirofumi, Y, Takahashi, A, Inoue, N, Takeuchi, K, Hatake, K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436080/ https://www.ncbi.nlm.nih.gov/pubmed/28430176 http://dx.doi.org/10.1038/bcj.2017.37

Ejemplares similares

Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
por: Kusano, Y, et al.
Publicado: (2017)

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
por: Kusano, Y, et al.
Publicado: (2017)

R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphoma
por: Mishima, Yuko, et al.
Publicado: (2012)

Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2017)

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)
por: Yokoyama, Masahiro, et al.
Publicado: (2021)

Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2)
por: Yokoyama, Masahiro, et al.
Publicado: (2019)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas
por: Tsuyama, Naoko, et al.
Publicado: (2017)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
por: Mishima, Y, et al.
Publicado: (2011)

Intravascular Large B-cell Lymphoma of the Bilateral Ovaries and Uterus in an Asymptomatic Patient with a t(11;22)(q23;q11) Constitutional Translocation
por: Shigematsu, Yasuyuki, et al.
Publicado: (2016)

Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Low Multiplication Value of Absolute Monocyte Count and Absolute Lymphocyte Count at Diagnosis May Predict Poor Prognosis in Neuroblastoma
por: Tamura, Akihiro, et al.
Publicado: (2020)

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis
por: Dobashi, Akito, et al.
Publicado: (2018)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Absolute Reticulocyte Count Acts as a Surrogate for Fetal Hemoglobin in Infants and Children with Sickle Cell Anemia
por: Meier, Emily Riehm, et al.
Publicado: (2015)

Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP
por: Kim, Joong-Keun, et al.
Publicado: (2014)

Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab
por: Ueda, Kosuke, et al.
Publicado: (2023)

Value of the use of absolute lymphocyte as surrogate for CD4 count in resource poor situations
por: Adegbamigbe, Oluwafemi Johanson, et al.
Publicado: (2014)

Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis
por: YAMAUCHI, TAKAHIRO, et al.
Publicado: (2015)

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
por: Shin, Su-Jin, et al.
Publicado: (2013)

CHOP mediates ASPP2-induced autophagic apoptosis in hepatoma cells by releasing Beclin-1 from Bcl-2 and inducing nuclear translocation of Bcl-2
por: Liu, K, et al.
Publicado: (2014)

P1118: PROGNOSTIC SIGNIFICANCE OF ABSOLUTE MONOCYTE COUNT AND LYMPHOCYTE TO MONOCYTE RATIO IN MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA
por: Li, Y., et al.
Publicado: (2022)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

R‐CHOP‐14 versus R‐CHOP‐14/CHASER for upfront autologous transplantation in diffuse large B‐cell lymphoma: JCOG0908 study
por: Kagami, Yoshitoyo, et al.
Publicado: (2020)

Clinical Response to CHOP vs. R-CHOP in Adult Patients with Diffuse Large B-Cell Lymphomas
por: Tariq, Ayesha, et al.
Publicado: (2018)

Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria
por: Barr, David A., et al.
Publicado: (2021)

Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy
por: Shirouchi, Yuko, et al.
Publicado: (2023)

Preoperative low absolute lymphocyte count to fibrinogen ratio correlated with poor survival in nonmetastatic colorectal cancer
por: Huang, Xiang, et al.
Publicado: (2022)

Biodistribution of locally or systemically transplanted osteoblast-like cells
por: Okabe, Y. T., et al.
Publicado: (2014)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Transforming growth factor beta 1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue.
por: Mahara, K., et al.
Publicado: (1994)

Simple on-line method of measuring the absolute ionization efficiency of an ion source
por: Nomura, T, et al.
Publicado: (1994)

R-CHOP-Associated Graves' Hyperthyroidism
por: Mora, Natalie, et al.
Publicado: (2019)

Postoperative Low Absolute Lymphocyte Counts may Predict Poor Outcomes of Hepatocellular Carcinoma After Liver Resection
por: Wang, Ming, et al.
Publicado: (2016)

Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma
por: Shah, Rema, et al.
Publicado: (2023)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
por: Ren, K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ad0huoganaem7le9joog835k6p